A physiologically based pharmacokinetic model for 2,4-toluenediamine leached from polyurethane foam-covered breast implants

Environmental Health Perspectives

Volumn 106, Issue 7, 1998, Pages 393-400

  Luu, Hoan My Do ^a,b   Hutter, Joseph C ^a   Bushar, Harry F ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Ctr Devices and Radiological Hlth   (United States)

Author keywords

2,4 Toluenediamine; Implant; PBPK; Physiologically based pharmacokinetic model; Polyester urethane; Risk assessment

Indexed keywords

2,4 DIAMINOTOLUENE; CARCINOGEN; POLYURETHAN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; BLOOD LEVEL; BREAST ENDOPROSTHESIS; CONTROLLED STUDY; DEGRADATION; EXPOSURE; FEMALE; FOAM; GASTROINTESTINAL TRACT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; LEACHING; LIVER; METABOLITE; MUSCLE; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; SUBCUTANEOUS DRUG ADMINISTRATION; URINE LEVEL;

EID: 0031725467     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.98106393     Document Type: Article

References (30)

1. Scott Paper Co. Polymer Foam Modification. US patent 858,127. 7 June 1957.
2. Picha GJ, Goldstein JA, Stohr E. Natural-Y Meme Polyurethane versus smooth silicons:analysis of the soft-tissue interaction from 3 days to 1 year in the rat animal model. Plast Reconstr Surg 85(6):903-916 (1990).
3. Smahel J. Tissue reactions to breast implants coated with Polyurethane. Plast Reconstr Surg 61(1):80-85 (1978).
4. Melmed EP, Polyurethane implants:A 6-year review of 416 patients. Plast Reconstr Surg 82(2):285-290 (1988).
5. Luu HMD, White KD. In-vitro detection of 2,4-and 2,6-TDA as degradation products of a polyesterurethane foam. Poly Degrad Stabil 42:245-251 (1993).
6. Luu HMD, Biles J, White KD. Characterization of polyesterurethane degradation Products. J Appl Bio Mater 5:1-7 (1994).
7. Amin P, Willie J, Slah K, Kydonieus A. Analysis of the extractive and hydrolytic behavior of microthane poly(ester-urethane) foam by high pressure liquid chromatography. J Biomed Mater Res 27:655-666 (1993).
8. Batich C, Williams J, King R. Toxic hydrolysis product from a biodegradable foam implant. J Biomed Mater Res 23:311-319 (1989).
9. Benoit MF. Degradation of polyurethane foams used in the Meme breast implant. J Biomed Mater Res 27:1341-1348 (1993).
10. Glinsukon T, Benjamin T, Grantham PH, Weisburger EK, Roller PP. Enzymic N-Acetylation of 2,4-toluenediamine by liver cytosols from various species. Xenobiotica 5(8):475-483 (1975).
11. Grantham PH, Mohan L, Benjamin T, Roller PP, Miller JR, Weisburger EK. Comparison of the metabolism of 2,4-toluenediamine in rats and mice. J Envron Pathol Toxicol 3:149-166 (1979).
12. Waring RH, Pheasant AE. Some phenolic metabolites of 2,4-toluenediamina in the rabbit, rat, and guinea pig. Xenobiotica 6(4):257-262 (1976).
13. Weisburger EK, Russfield AB, Homburger F, Weisburger JH, Boger E, Van Dongen CG, Chu KC. Testing of twenty-one environmental aromatic amines or derivatives for long term toxicity or carcinogenicity. J Environ Path Toxicol 2:325-356 (1978).
14. Ito N, Hiasa Y, Konishi Y, Marugami M, The development of carcinoma in liver of rats treated with M-toluylenediamine and the synergistic and antagonistic effects with other chemicals, Cancer Res 29(5):1137-1145 (1969).
15. National Cancer Institute. Bioassay of 2,4-Diaminotoluene for Possible Carcinogenicity. NCI Technical Report Series No. 162. Bethesda, MD:National Cancer Institute, 1979.
16. 14C]toluane 2,4-diamine in Fisher 344 rats, Toxicol Appl Pharmacol 124:181-190 (1994).
17. Kadlubar FF, Mammons GJ, The role of cytochrome P-450 in the metabolism of chemical carcinogens, In:Mammalian Cytochromes P-450, vol II (Guengerich FP, ed). Boca Raton, FLCRC Press, 1987;81-130.
18. IARC, 2,4-Diaminotoluene. In:IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. Vol 16:Some Aromatic Amines and Related Compounds-Hair Dyes, Colouring Agents and Miscellaneous Industrial Chemicals. Lyon:International Agency for Research on Cancer, 1978;83-95.
19. WHO. Diaminotoluenes, Environmental Health Criteria No 74. Geneva:World Health Organization, 1987.
20. Chan SC, Birdsell DC, Gradee CY, Detection of toluenediamines in the urine of a patient with polyurethane covered breast implants. Clin Chem 37(5):756-758 (1991).
21. Chan SC, Birdsell DC, Gradee CY. Urinary excretion of free toluenediamines in a patient with polyurethanecovered breast implants. Clin Chem 37(12):2143-2145 (1991).
22. Sepal O, Henschler D, Czech S, Eckert P, Sabbionl G. Exposure to toluenediamines from polyurethane-covered breast implants. Toxicol Lett 77:371-378 (1995).
23. Food and Drug Administration. CDRH Toxicology Risk Assessment Committee Report on Polyester Polyurethane Foam Covering of Silicone Gel Filled Breast Implants. FDA Memorandum, 22 July 1991.
24. Expert Panel of the Canadian Medical Association. Safety of polyurethane-covered breast implants. Can Med Assoc J 145:1125-1128 (1991).
25. Krishnan K, Anderson ME. Physiologically based pharmacokinetic modeling in toxicology. In:Principles and Methods of Toxicology (Hayes WA, ed). 3rd ed. New York:Raven Press, 1994;149-188.
26. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Bellies RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407-484 (1997).
27. Ramsey JR, Anderson ME. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans, Toxicol Appl Pharmaccl 73:159-175 (1984).
28. Anderson ME, Clewell HJ, Gargas ML, Smith FA, Reitz RH. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol Appl Pharmacol 87:185-205 (1987).
29. FDA. Discretionary Postmarket Surveillance Protocol for the Meme and Replicon Polyester/ Polyurethane-covered Mammary Products. DPS 920001. Rockville, MD:Food and Drug Administration, 1992.
30. Chasseaud LF, Role of toxicokinetics in toxicity testing. In:Drug Toxicokinetics (Welling P, Iglesia FA, eds, Drug and Chemical Toxicology, Vol 9. New York:Marcel Dekker, Inc. 1993;105-142.